SAN DIEGO, Nov. 24, 2015 /PRNewswire/ -- Mast
Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage
biopharmaceutical company leveraging its molecular adhesion and
sealant technology (MAST) platform to develop novel therapies for
sickle cell disease, heart failure and stroke, today announced that
the Company's Chief Executive Officer, Brian M. Culley, will present at the Piper
Jaffray 27th Annual Healthcare Conference on
Tuesday, December 1, 2015 at
4:30pm Eastern Time at the New York
Palace hotel in New York City.
Interested parties can access a live audio webcast of the
fireside chat on the Mast Therapeutics web site at
www.masttherapeutics.com. An archived presentation will be
available on the web site for 30 days.
About Mast Therapeutics
Mast Therapeutics, Inc. is a
publicly traded biopharmaceutical company headquartered in
San Diego, California. The
Company is leveraging its MAST platform, derived from over two
decades of clinical, nonclinical and manufacturing experience with
purified and non-purified poloxamers, to develop vepoloxamer (also
known as MST-188), its lead product candidate, for serious or
life-threatening diseases and conditions typically characterized by
impaired microvascular blood flow and damaged cell membranes.
The Company is also developing AIR001, a sodium nitrite solution
for inhalation via nebulizer, for the treatment of heart failure
with preserved ejection fraction (HFpEF).
Vepoloxamer is an investigational new drug being tested in a
pivotal Phase 3 study called EPIC for the treatment of
vaso-occlusive crisis in patients with sickle cell disease and in a
Phase 2 study for the treatment of patients with chronic heart
failure. AIR001 is an investigational new drug being tested
in two institution-sponsored Phase 2a studies in patients with
HFpEF. More information can be found on the Company's web site at
www.masttherapeutics.com. (Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Forward Looking Statements
Mast Therapeutics cautions
you that statements included in this press release or made during
the presentation announced hereby that are not a description of
historical facts are forward-looking statements that are based on
the Company's current expectations and assumptions. Such
forward-looking statements may include, but are not limited to,
statements relating to prospects for successful development and
commercialization of, and patent protection for, the Company's
investigational drugs, including vepoloxamer and AIR001, and
anticipated timing of achievement of development milestones, such
as commencement and completion of clinical studies or regulatory
activities, and of announcement of study data. Among the factors
that could cause or contribute to material differences between the
Company's actual results and the expectations indicated by the
forward-looking statements are risks and uncertainties that
include, but are not limited to: the uncertainty of outcomes in
ongoing and future studies of the Company's product candidates and
the risk that its product candidates, including vepoloxamer, may
not demonstrate adequate safety, efficacy or tolerability in one or
more such studies, including EPIC and the Phase 2 study of
vepoloxamer in chronic heart failure; delays in the commencement or
completion of clinical studies, including as a result of
difficulties in obtaining regulatory agency agreement on clinical
development plans or clinical study design, opening trial sites,
enrolling study subjects, manufacturing sufficient quantities of
clinical trial material, being subject to a "clinical hold," and/or
suspension or termination of a clinical study, including due to
patient safety concerns or lack of funding; the risk that, even if
planned clinical studies are successful, the FDA or other
regulatory agencies may determine they are not sufficient to
support a new drug application; the potential that, even if
clinical studies of a product candidate in one indication are
successful, clinical studies in another indication may not be
successful; the potential for additional nonclinical or clinical
studies to be required prior to initiation of a planned clinical
study; the Company's reliance on contract research organizations
(CROs), contract manufacturing organizations (CMOs), and other
third parties to assist in the conduct of important aspects of
development of its product candidates, including clinical studies,
manufacturing, and regulatory activities for its product
candidates, and that such third parties may fail to perform as
expected; the risk that the Company may be required to repay its
outstanding debt obligations at a time that could be detrimental to
its financial condition, operations and/or business strategy; the
Company's ability to obtain additional funding on a timely basis or
on acceptable terms, or at all; the potential for the Company to
delay, reduce or discontinue current and/or planned development
activities, including clinical studies, partner its product
candidates at inopportune times or pursue less expensive but
higher-risk and/or lower return development paths if it is unable
to raise sufficient additional capital as needed; the risk that,
even if the Company successfully develops a product candidate in
one or more indications, it may not realize commercial success and
may never achieve profitability; the risk that the Company is not
able to adequately protect its intellectual property rights,
through patents or otherwise, and prevent competitors from
duplicating or developing equivalent versions of its product
candidates or that the use or manufacture of its products or
product candidates infringe the proprietary rights of others; and
other risks and uncertainties more fully described in the Company's
press releases and periodic filings with the Securities and
Exchange Commission. The Company's public filings with the
Securities and Exchange Commission are available at
www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. Mast
Therapeutics does not intend to revise or update any
forward-looking statement set forth in this press release or made
during the presentation announced hereby to reflect events or
circumstances arising after the date when made, except as may be
required by law.
Logo -
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mast-therapeutics-to-present-at-the-piper-jaffray-27th-annual-healthcare-conference-300183470.html
SOURCE Mast Therapeutics